Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
PR Newswire Asia
· *Oral session:*ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer
· *Three..
· *Oral session:*ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer
· *Three..
*Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat*
*PLANEGG..
Irena Stoynova was diagnosed with non-Hodgkin lymphoma in June 2021